Effectiveness of montelukast in overweight and obese atopic asthmatics

Ann Allergy Asthma Immunol. 2017 Aug;119(2):189-190. doi: 10.1016/j.anai.2017.05.024. Epub 2017 Jun 28.

Authors

Sherry Farzan¹, Sundas Khan², Claudia Elera², James Tsang³, Meredith Akerman³, James DeVoti⁴

Affiliations

¹ Division of Allergy and Immunology, Northwell Health System, Great Neck, New York. Electronic address: [email protected].
² Department of Medicine, Northwell Health System, Manhasset, New York.
³ Division of Biostatistics, Feinstein Institute for Medical Research, Northwell Health System, Manhasset, New York.
⁴ Center for Immunology and Inflammation, Feinstein Institute for Biomedical Research, Northwell Health System, Manhasset, New York.

PMID: 28668546
DOI: 10.1016/j.anai.2017.05.024

No abstract available

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Acetates / therapeutic use*
Adolescent
Anti-Asthmatic Agents / therapeutic use*
Asthma / drug therapy*
Asthma / physiopathology
Child
Cyclopropanes
Double-Blind Method
Female
Humans
Male
Obesity / complications*
Overweight / complications*
Prospective Studies
Quinolines / therapeutic use*
Sulfides

Substances

Acetates
Anti-Asthmatic Agents
Cyclopropanes
Quinolines
Sulfides
montelukast

Associated data

ClinicalTrials.gov/NCT01329939